Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Taiwan Precision Medicine Initiative provides a cohort for large-scale studies.

Nature·2025
Same author

Associations of COVID-19 vaccination with risks for post-infectious cardiovascular complications: an international cohort study in cancer patients with SARS-CoV-2 infection.

Lancet regional health. Americas·2025
Same author

AptBCis1, An Aptamer-Cisplatin Conjugate, Is Effective in Lung Cancer Leptomeningeal Carcinomatosis.

ACS nano·2024
Same author

Response to Letter to the Editor: "Factors Other Than Low-Dose Computed Tomography Screening Related to Stage Shift and Improved Survival of Lung Cancer".

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2023
Same author

LCRMP-1 is required for spermatogenesis and stabilises spermatid F-actin organization via the PI3K-Akt pathway.

Communications biology·2023
Same author

Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response.

Science advances·2023

Related Experiment Video

Updated: Feb 22, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.4K

A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect.

Bo-Tsang Huang1, Wei-Yun Lai1, Yi-Chung Chang1

  • 1Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

Molecular Therapy. Nucleic Acids
|September 18, 2017
PubMed
Summary

Researchers developed aptCTLA-4, a novel DNA aptamer that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This aptamer shows promise in cancer immunotherapy by promoting lymphocyte proliferation and inhibiting tumor growth.

Keywords:
CTLA-4aptamercancerimmunotherapy

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.2K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Experiment Videos

Last Updated: Feb 22, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.4K
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.2K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Area of Science:

  • Biotechnology
  • Immunology
  • Cancer Research

Background:

  • Cancer immunotherapy has been revolutionized by cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade.
  • Monoclonal antibodies are the current standard for CTLA-4-targeted therapies.
  • Aptamers offer an alternative with antibody-mimicking capabilities.

Purpose of the Study:

  • To develop and characterize a novel DNA aptamer targeting CTLA-4.
  • To evaluate the therapeutic potential of this aptamer in preclinical cancer models.

Main Methods:

  • Systematic Evolution of Ligands by Exponential Enrichment (SELEX) was employed for aptamer identification.
  • High-throughput sequencing was used to identify high-affinity aptamers.
  • In vitro and in vivo assays were conducted to assess aptamer stability, function, and efficacy.

Main Results:

  • A high-affinity CTLA-4-antagonizing DNA aptamer, aptCTLA-4, was identified with a dissociation constant of 11.84 nM.
  • aptCTLA-4 demonstrated stability in serum conditions.
  • The aptamer promoted lymphocyte proliferation and inhibited tumor growth in cellular and animal models.

Conclusions:

  • The study successfully developed a functional CTLA-4-targeting aptamer, aptCTLA-4.
  • aptCTLA-4 exhibits promising preclinical efficacy for cancer immunotherapy.
  • This aptamer holds significant translational potential as an alternative therapeutic agent.